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tracted QT interval (QTI) adaptation to abrupt heart rate (HR) changes
has been identified as a clinical arrhythmic risk marker. This study
investigates the ionic mechanisms of QTI rate adaptation and its
relationship to arrhythmic risk. Computer simulations and experimen-
tal recordings in human and canine ventricular tissue were used to
investigate the ionic basis of QTI and action potential duration (APD)
to abrupt changes in HR with a protocol commonly used in clinical
studies. The time for 90% QTI adaptation is 3.5 min in simulations, in
agreement with experimental and clinical data in humans. APD
adaptation follows similar dynamics, being faster in midmyocardial
cells (2.5 min) than in endocardial and epicardial cells (3.5 min). Both
QTI and APD adapt in two phases following an abrupt HR change: a
fast initial phase with time constant  30 s, mainly related to L-type
calcium and slow-delayed rectifier potassium current, and a second
slow phase of 2 min driven by intracellular sodium concentration
([Na]i) dynamics. Alterations in [Na]i dynamics due to Na/K
pump current inhibition result in protracted rate adaptation and are
associated with increased proarrhythmic risk, as indicated by action
potential triangulation and faster L-type calcium current recovery
from inactivation, leading to the formation of early afterdepolariza-
tions. In conclusion, this study suggests that protracted QTI adaptation
could be an indicator of altered [Na]i dynamics following Na/K
pump inhibition as it occurs in patients with ischemia or heart failure.
An increased risk of cardiac arrhythmias in patients with protracted
rate adaptation may be due to an increased risk of early afterdepolar-
ization formation.
action potentials; ventricles; ion channels; arrhythmia; computers
CLINICAL, EXPERIMENTAL, AND theoretical studies have shown that
an abrupt change in heart rate (HR) results in the progressive
adaptation of the QT interval (QTI) in the ECG because of
short-term cardiac memory effects (2, 3, 22, 29, 35, 36).
Patients exhibiting protracted QTI HR adaptation dynamics
have been identified as at increased risk of experiencing car-
diac arrhythmias and sudden cardiac death (22, 35). Further-
more, clinical data also suggest that the extent of amiodarone-
induced acceleration of QTI HR adaptation could be used as a
therapeutic marker of drug efficacy (37). However, despite
strong evidence suggesting an important role of short-term
cardiac memory in arrhythmogenesis, the underlying mecha-
nisms are still controversial.
The present study investigates the ionic basis of QTI rate
adaptation in human ventricular tissue and its link to proar-
rhythmic mechanisms. Computer simulations and experiments
were conducted to identify the specific mechanisms of ionic
transport that determine QTI rate adaptation and how alter-
ations in those mechanisms might result in arrhythmic events.
Key simulation predictions were evaluated using experimental
and clinical data from the literature and a limited set of
experiments in humans performed in this study. Ionic mecha-
nisms underlying HR adaptation were further investigated
using simulations and experiments in both humans and dogs
because of their similar repolarization mechanisms and the
greater availability of canine tissue compared with that of
humans (41).
MATERIALS AND METHODS
Computer Modeling and Simulation
Human (38) and canine (10) ventricular cell models were used to
investigate short-term memory mechanisms. Computer simulations of
electrical propagation and pseudo-ECG (pECG) (21) were conducted
using a transmural one-dimensional fiber model, consisting of 100
cells [30% endocardial (Endo), 30% midmyocardial (Mid), and 40%
epicardial (Epi) cells (12, 38)]. A 1-ms square stimulus pulse of 1.5
times diastolic threshold was applied to the endocardium. Integration
was performed using the forward Euler method with a 0.02-ms time
step and 0.015-cm space step. pECG peaks and boundaries were
identified using an automatic wavelet transform-based delineation
system (33). pECG QTI was measured as the time interval between
the QRS complex onset and the T-wave end.
Characterization of Ventricular HR Adaptation Dynamics
The rate adaptation of QTI and action potential (AP) duration
(APD) at 90% repolarization was evaluated (18, 29): pacing at a cycle
length (CL) of 1,000 ms was applied until steady state, followed by a
CL of 600 ms for 10 min and back to a CL of 1,000 ms for an
additional 10 min. Fast and slow phases in QTI and APD rate
adaptation were identified, and time constants () of their dynamics
were obtained by fitting to: f(t)  a  be(tc)/.
Time constants fast and slow, characterizing each of the two
adaptation phases, were obtained, both after the CL increase and
decrease. In cases where the fast phase consisted of only two data
points, then f(t)  bet/ was used to derive fast.
QTI or APD adaptation is defined as protracted when the associated
time constant slow is abnormally long (see RESULTS for a detailed
description), which is related to irregularities in APD adaptation
dynamics and the generation of afterdepolarizations.
Evaluation of Proarrhythmic Risk in Simulation
To investigate the ionic mechanisms of rate adaptation and its
relationship to risk, adaptation dynamics and arrhythmic risk markers
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were quantified for control and also following 15 and 30%
changes in specific model parameters. The arrhythmic risk markers
(30) considered were 1) AP triangulation, quantified as   APD/
APD50, where APD50 denotes APD at 50% repolarization, considered
to be an indicator of an early afterdepolarization (EAD) occurrence
(34); 2) APD restitution (APDR) curve slope at a diastolic interval of
60 ms (26), determined using both S1-S2 and dynamic protocols (38),
SS1-S2 and Sdyn, respectively; and 3) calcium current reactivation, as
the product 	 of the inactivation gates [f, f2, and fcass (38)] of the
L-type calcium current (ICaL) computed at 90% repolarization for
steady state at a CL of 1,000 ms (42).
Experimental Methods
Experiments were performed to validate key simulation results,
when specific data were not available in the literature. Experiments
were conducted in human ventricular tissue when available (n  2
tissue samples); otherwise, right ventricle papillary muscles isolated
from adult mongrel dogs hearts (n  21) were used (8–20 kg, either
sex) (40). All animal experiments were conducted in compliance with
the Guide for the Care and Use of Laboratory Animals (NIH Publi-
cation No. 85-23, Revised 1996), and the protocol was approved by
the Ethical Committee for the Protection of Animals in Research of
the University of Szeged, Hungary (I-74-125-2007) and by the De-
partment of Animal Health and Food Control of the Ministry of
Agriculture and Rural Development (XIII/01031/000/2008). Regard-
ing human experiments, undiseased human hearts that were techni-
cally not usable for transplantation (based on logistical and not on
patient-related reasons) were obtained from general organ donors.
Before cardiac explantation, organ donor patients did not receive
medication except dobutamine, furosemide, and plasma expanders.
The investigations conform with the principles outlined in the Dec-
laration of Helsinki of the World Medical Association. The experi-
mental procedures and protocols were approved by the Ethical Re-
view Board of the Medical Center of the University of Szeged,
Hungary (No. 51-57/1997 OEJ). Human right ventricular papillary
muscle preparations were dissected from donor hearts stored in
cardioplegic solution at 4°C for 3 to 4 h before placing them into
oxygenated modified Locke’s solution containing (in mM) 120 NaCl,
4 KCl, 1.0 CaCl2, 1 MgCl2, 22 NaHCO3, and 11 glucose. The pH of
this solution was set to 7.4  0.05 when saturated with the mixture of
95% O2 and 5% CO2 at 37°C.
Transmembrane APs were recorded using the conventional micro-
electrode technique as described previously (40). APD HR adaptation
was evaluated using the same protocol as in the simulations, both in
control (in humans and dogs) and in the presence of the following
drug concentrations (in dogs): 0.2 and 0.6 
M strophanthin G (n  5
and 7), 1 and 3 
M nisoldipine (n  1), 30 
M BaCl2 (n  2), 0.25

M HMR-1556 (n  3), and 0.1 
M dofetilide (n  3). Strophanthin
G and BaCl2 were dissolved in distilled water to give stock solution
concentrations of 1 and 50 mM, respectively. Nisoldipine was dis-
solved in 100% ethanol stock solution (1 mM). HMR-1556 was
dissolved in DMSO stock solution (1 mM).
RESULTS
Ventricular Rate Adaptation
QTI adaptation. Figure 1A illustrates QTI adaptation kinet-
ics in humans from simulations (left) and clinical data (29)
(right). Figure 1B shows simulated pECG for the first beat
following HR acceleration (left) and deceleration (right) and
when the new steady state is reached. QTI adaptation after a
Fig. 1. A, left: simulated QT interval (QTI) adaptation in human pseudo-ECG for cycle length (CL) of 1,000 to 600 to 1,000 ms. A, right: QTI adaptation in human
ECG recordings for 50 or 110 beats/min in increments or decrements of 20, 40, and 60 beats/min (modified and redrawn from original graphs from Ref. 29).
Time required for 90% QTI rate adaptation (t90) is presented. B: simulated pseudo-ECGs corresponding to first (dotted line) and last (solid line) beats after CL
decrease (left) and CL increase (right). C: t90 values for simulated pseudo-ECGs and clinical human ECGs. HR, heart rate; Acc, acceleration; Dec, deceleration;
TP06, human ventricular cell model developed by ten Tusscher and Panfilov (38) in 2006.
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step CL decrease/increase begins with a fast QTI shortening/
lengthening during the initial beats after the HR change (fast 
17/34 s), followed by a second slow accommodation (slow 
122/122 s). In the simulations, the time (t90) required for QTI
to complete 90% of its adaptation in humans is 217/224 s follow-
ing HR acceleration/deceleration. As shown in Fig. 1C, simulation
values for t90 are within the wide range reported clinically.
A sensitivity analysis was performed to assess the depen-
dence of QTI rate adaptation dynamics on CL change magni-
tude (mCL) and on the initial CL (iCL). Values for mCL consid-
ered were 200, 400, and 600 ms, and values for iCL were 1,000
and 1,400 ms. No statistically significant differences (analysis of
variance, P  0.05) in t90 are observed when varying mCL or iCL.
APD adaptation. Figure 2, A and B, illustrates APD HR
adaptation in simulated Endo (top), Mid (middle), and Epi
(bottom) human ventricular cells. Figure 2A shows the time
course of APD adaptation, and Fig. 2B illustrates the AP
corresponding to the first beat and the new steady state follow-
Fig. 2. A: simulated action potential (AP) duration (APD) adaptation in humans for CL of 1,000 to 600 to 1,000 ms for endocardial (Endo; top), midmyocardial
(Mid; middle), and epicardial (Epi; bottom) cardiomyocytes. B: simulated APs corresponding to first (dotted line) and last (solid line) beats after CL decrease
(left) and CL increase (right) for human Endo (top), Mid (middle), and Epi (bottom) cardiomyocytes. C: experimental APD adaptation in humans for CL of
750–410 ms (left, modified and redrawn from original graphs from Ref. 18) and for CL of 1,000–600 ms (right, this study). D: t90 values for simulated and
experimental human APs.
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ing HR acceleration (left) and deceleration (right) for the three
cell types. Figure 2C presents experimental APD adaptation
measured in human ventricular endocardium (18), as well as in
human papillary muscle, measured in this study.
It is clear that APD HR adaptation dynamics are similar in
human simulations and experiments (18) and comparable with
QTI HR adaptation dynamics (shown in Fig. 1), consisting of
a fast and slow phase (fast  13/26 s after CL decrease/
increase for Endo, 6/14 s for Mid, and 13/26 s for Epi cells; and
slow  126/122 s after CL decrease/increase for Endo, 128/
122 s for Mid, and 126/123 s for Epi cells). This suggests that
QTI HR adaptation is a manifestation of cellular APD HR
adaptation. As shown in Fig. 2D, simulation values for t90 are
within the range observed experimentally. Furthermore, simu-
lations with both the human and the dog models yield similar
rate adaptation dynamics, although slightly slower in dog (t90 
282/311 s in canine and t90  213/218 s in human Epi cells for
HR acceleration/deceleration, respectively). Analogous to the re-
sults reported for QTI in this study, no statistically significant
differences in t90 for APD adaptation are found when varying
mCL or iCL.
Ionic Mechanisms of APD Rate Adaptation
Figures 3 and 4 illustrate the ionic mechanisms of APD HR
adaptation in humans. Each panel in Fig. 3 represents the
change in peak value of each ionic current [slow delayed
rectifier potassium current (IKs), ICaL, transient outward potas-
sium current (Ito), rapid delayed rectifier potassium current
(IKr), inward rectifier potassium current (IK1), fast sodium
current (INa), Na/Ca2 exchanger current (INaCa), and
Na/K pump current (INaK)] or intracellular sodium and
calcium ion concentration ([Na]i and [Ca2]i), as a function
of APD for the beats following HR acceleration (analogous
results were obtained for HR deceleration; graphics not
shown). The numbers shown in each graph indicate the number
of beats following the CL change. Bar graphs in Fig. 4 show
the percentage of total change in peak values of each ionic
current or intracellular ion concentration that occurred during
the fast (top) and slow (bottom) phase of HR adaptation. The
ionic mechanisms involved in each of the adaptation phases,
fast and slow, are further described in the following.
Initial fast phase of adaptation. Figures 3 and 4 show that
ICaL and IKs experience the greatest percentage of total change
during the initial phase of rate adaptation and are key mecha-
nisms driving that phase. Other ionic currents, such as Ito,
present a percentage of change similar to IKs, but these changes
are a consequence (and not a cause) of APD adaptation, since
variations in conductance and/or kinetics do not affect fast.
Figure 5A further illustrates the role that the dynamics of the
ICaL slow voltage-dependent inactivation gate (f) and the IKs
Fig. 3. Peak values for IKs, ICaL, Ito, IKr, IK1, INa, INaCa, INaK, [Na]i, and [Ca2]i (see main text for definitions of abbreviations) as a function of APD during
adaptation for CL varying from 1,000 to 600 ms in humans. Beat number after step CL change is shown.
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activation gate (xs) play in the fast phase of human APD
adaptation. Indeed, a sudden decrease in CL results in an
insufficient time for f to fully recover (f  1) (Fig. 5A, top),
whereas IKs is unable to completely deactivate (xs  0) at the
end of each beat. The resulting decrease in inward and increase
in outward currents contribute to APD shortening following
HR acceleration. To further illustrate the importance of f and xs
in the initial adaptation phase, Fig. 5A, right, shows APD
adaptation dynamics for control and for a simulation where
beat-to-beat differences in f and xs are eliminated by fixing
them to their steady-state values for a CL of 1,000 ms (f 
0.9774 and xs  0.003225, respectively). Results show that
eliminating beat-to-beat differences in f and xs leads to the
abolishment of the fast phase of APD adaptation. Similar
mechanisms are observed using the canine ventricular model
(not shown).
Simulations were performed to evaluate the effect of mod-
erate changes (15–30%) in values of key parameters defining
gate kinetics and conductances of all ionic currents in the
human ventricular model. The effect of those changes on time
constants for the fast and slow adaptation phases (fast and
slow), as well as the arrhythmic risk indicators , , SS1-S2, and
Sdyn, were quantified. Simulation results are shown in Fig. 6 for
the parameters with greatest influence on human APD HR
adaptation. As previously discussed and illustrated in Figs.
3–5, Fig. 6 (first row) also shows that fast is greatly sensitive
to ICaL inactivation and IKs activation kinetics and thus mod-
erate changes of up to 30% in f and xs significantly alter fast.
Changes of up to 30% in ionic current conductances have only
a negligible effect on fast (Fig. 6, first row). Additional
simulations and experiments were conducted to evaluate
whether large degrees (70%) of ion channel block could
affect fast. Results for human ventricular myocyte simulations
and canine experiments are shown in Fig. 7, left and right,
respectively, for ICaL (A), IKs (B), IK1 (C), and IKr (D). Results
show that ICaL block by 70–90% significantly increases fast by
54–249/107–223% following HR acceleration/deceleration us-
ing the human model (Fig. 7A, left). Qualitatively similar
results are obtained using the canine model (not shown),
although the effects are more pronounced in dogs, reaching
500% change in fast for full ICaL block. In the experiments,
ICaL block using 1 or 3 
M nisoldipine also results in increased
fast in canine papillary muscle (Fig. 7A, right), although to a
lower extent than in the simulations, i.e., by 33/72% and
54/94% following HR acceleration/deceleration, respectively.
Furthermore, simulated 90–100% IKs inhibition results in a
significant decrease in fast by 71–82/63–76% following HR
acceleration/deceleration in humans (Fig. 7B, left), whereas in
dogs, the simulated effect is 10%. In the canine experiments,
IKs block by 0.25 
M HMR-1556 (full block) led to 16/20%
decrease in fast following HR acceleration/deceleration (Fig.
7B, right). The effect of IK1 and IKr block on fast was also
explored. The results in Fig. 7C, left, show that simulated IK1
block by 80–90% results in a 6–40/3–22% increase in fast
following HR acceleration/deceleration in humans, whereas in
dogs it results in a 39–67/41–67% decrease in fast. In the
experiments, 30 
M BaCl2 (estimated 80% block) results in a
28/11% decrease in fast (Fig. 7C, right). Full IKr block results
in a 7/9% increase in fast with the human model (Fig. 7D, left),
but in the canine model this leads to EADs, making the fast
measurement impossible. In the canine experiments with 0.1

M dofetilide, there is a 10/10% decrease in fast following HR
acceleration/deceleration (Fig. 7D, right). Overall, the simula-
tions and experiments show a good qualitative agreement in the
Fig. 4. Percentage of total change in peak value for each ionic current and
concentration during fast (top) and slow (bottom) phases of APD adaptation for
CL varying from 1,000 to 600 ms (HRacc) and from 600 to 1,000 ms (HRdec).
Nai, [Na]i; Cai, [Ca2]i.
Fig. 5. Mechanisms of the fast and slow
phases of APD adaptation after abrupt sus-
tained CL changes (1,000 to 600 to 1,000 ms)
in humans. A, left: time course of the ICaL
slow voltage-dependent inactivation gate f
and the IKs activation gate xs for the first 5
beats after CL decrease for control (solid line)
and when gate variables are preset to the
steady-state value for CL of 1,000 ms at the
beginning of each beat (dotted line). A, right:
corresponding APD time courses. B, left: time
course of [Na]i for control (solid line) and
when clamped to its steady-state value for
each CL (dotted line). B, right: corresponding
APD time courses.
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effect of specific ionic current block on fast, although specific
quantitative differences are found, which are further analyzed
in DISCUSSION.
Slow phase of adaptation. APD adaptation finishes with a
slow phase, during which [Na]i and [Ca2]i, as well as INaK,
INaCa, and several potassium currents, experience important
changes (Figs. 3 and 4). As shown in Fig. 5B, left, following
HR acceleration, [Na]i slowly accumulates (control trace),
which causes an increase in repolarization current via enhanced
activity of INaK and INaCa (operating in reverse mode), resulting
in a progressive APD shortening. With the use of both human
and canine ventricular models, clamping [Na]i to its steady-
state value eliminates the slow APD adaptation phase (Fig. 5B,
[Na]i clamp in humans). This suggests that [Na]i dynamics
determine the slow phase of adaptation and that changes in
potassium currents depicted in Figs. 3 and 4 are secondary to
APD alterations caused by sodium regulation.
The results in Fig. 6 confirm the importance of INaK in the
slow phase of APD adaptation: INaK maximal conductance is
the only model parameter that when altered moderately (up to
30%) exerts a significant influence in slow in both humans and
dogs. Figure 8A shows that INaK inhibition by 30% results in an
increase in slow by 60% in virtual humans (Fig. 8A, left) and
by 150% in virtual canine Epi myocytes, whereas 0.6 
M
strophanthin G results in an 100% increase in slow in canine
experiments (Fig. 8A, right). IK1 and IKr block are also found
to have an impact on the slow APD adaptation, although only
in dogs, not in humans, and only for almost complete block.
Specifically, 90% IK1 block leads to a 30% decrease in slow in
both simulations and experiments in dogs but only to a 10%
decrease in human simulations. Full IKr block is associated with
25% increase in slow in experiments in dogs but results in10%
change in slow in humans. The effects of ICaL or IKs block on slow are
negligible.
APD HR Adaptation and Arrhythmic Risk
In this section, the link between protracted QTI and APD
HR adaptation dynamics and arrhythmic risk suggested by
clinical studies (19, 35) is investigated. As shown in Fig. 6, fast
ICaL inactivation and IKs activation (i.e., decrease in f or xs,
respectively) lead to large fast values and to a simultaneously
flattening of restitution curves, an enhanced AP triangulation
(associated with increased risk of EAD development), and a
decrease and an increase in 	, respectively (protection against
and increased likelihood of ICaL reactivation during AP repo-
Fig. 6. Changes in time constants for fast (fast, first row) and slow (slow, second row) phases of APD adaptation (solid line for HR acceleration for CL of 1,000
to 600 ms, and dotted line for HR deceleration for CL of 600 to 1000 ms), degree of ICaL recovery from inactivation at 90% repolarization (	, third row), AP
triangulation (, fourth row), S1-S2 restitution slope (SS1-S2, fifth row), and dynamic restitution slope (Sdyn, sixth row) induced by  15–30% variations in time
constant of slow voltage-dependent ICaL inactivation gate f (f, first column), time constant of IKs activation gate xs (xs, second column), ICaL maximal
conductance (GCaL, third column), IKs maximal conductance (GKs, fourth column), and maximal INaK (GNaK, fifth column).
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larization, respectively). Despite the enhancement of AP trian-
gulation associated with large fast values, no afterdepolariza-
tions were observed in the simulations for 60% changes in f,
xs, ICaL maximal conductance, and IKs maximal conductance,
although a 10-fold increase in fast was obtained for a 60%
reduction in f.
Regarding the slow phase of APD adaptation, Fig. 6 shows
that INaK inhibition results in an increase in slow and also an
increased 	 and , suggesting the increased likelihood of EAD
generation (24, 27, 42). Indeed, INaK inhibition by 30% in
simulations and by 0.6 
M strophanthin G in experiments
results in an increase in  from 1.11 to 1.15 and from 1.20 to
Fig. 7. Effect of ion channel block on APD rate adaptation dynamics. Left: simulation results in human ventricular cardiomyocyte. Right: experimental recordings
in canine papillary muscle for control (solid lines) and for the following: ICaL block by 70–80-90% in simulations and by 1 (A, top) and 3 
M (A, bottom)
nisoldipine in experiments, IKs block by 90–100% in simulations and by 0.25 
M HMR-1556 in experiments (B), IK1 block by 80–90% in simulations and by
30 
M BaCl2 in experiments (C), and IKr block by 100% in simulations and by 0.1 
M dofetilide in experiments (D). All experimental curves represent average
over experiments. Values for percent changes in the time constant of the fast phase of APD rate adaptation (fast) induced by each intervention are also shown.
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Fig. 8. A: effect of Na/K pump inhibition on the slow phase of APD rate adaptation. A: simulated (left) and experimental (right) APD adaptation in control
(solid line) and for Na/K pump inhibition (dotted line) by 10–20-30% in simulated human ventricular cardiomyocytes and by 0.2 (top) and 0.6 
M (bottom)
strophanthin G (Stroph) in canine experiments. Experimental curves represent average over experiments. B: early afterdepolarization generated following CL
increase from 600 to 1,000 ms for simulated 60% INaK inhibition. C–G: corresponding time course of [Ca2]i, Irel, INaCa, ICaL, and calcium-dependent inactivation
gate fcass of ICaL. See main text for definitions of abbreviations. V, voltage.
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1.33, respectively. EADs are observed in the simulations for
INaK inhibition by 60% following HR deceleration, for all cell
types in both humans and dogs. An example of EADs under
those conditions in a simulated human ventricular myocyte is
shown in Fig. 8B. Increasing the degree of INaK inhibition 
35% results in a significant increase in slow: slow  380 s and
1,610 s for 35 and 40% of INaK inhibition, respectively. In
addition, INaK inhibition degrees  40% lead to oscillations in
APD adaptation dynamics and EADs, which prevent its char-
acterization using exponential functions. Based on our results,
APD rate adaptation is defined as protracted when associated
slow  380 s. The mechanisms of EAD formation are the same
in both humans and dogs: severe INaK inhibition results in an
increase in [Na]i levels, and thus in INaCa-mediated calcium
influx (Fig. 8C), which increases [Ca2]i and calcium release
from the sarcoplasmic reticulum (Irel, Fig. 8D). This gives rise
to the enhanced depolarizing current via INaCa and ICaL (Fig. 8,
E–G) and, consequently, EAD formation.
DISCUSSION
The clinical relevance of ventricular rate adaptation has been
emphasized in a number of studies (15, 22, 45) and is high-
lighted by the frequent involvement of sudden changes in CL
in the initiation of lethal arrhythmias. In the present study, a
synergistic combination of theoretical and experimental meth-
ods is used to investigate the ionic basis of QTI and APD HR
adaptation and their link to proarrhythmic mechanisms. Sim-
ulation predictions on QTI and APD adaptation dynamics in
humans were validated using experimental and clinical data
available in the literature, and key ionic mechanisms of ven-
tricular HR adaptation in humans were identified. Because of
limitations in the availability of human tissue and similarities
in repolarization mechanisms in humans and dogs, further
investigations of the ionic basis of ventricular HR adaptation
were performed using a combination of simulations and ex-
periments in humans and dogs. The results show that both QTI
and APD HR adaptation follow similar dynamics, consisting of
two phases, fast and slow, driven by ICaL and IKs kinetics and
conductances, and [Na]i dynamics and INaK, respectively. Our
results suggest that protracted QTI rate adaptation (defined by
slow  380 s), as measured from the surface ECG of patients
at high arrhythmic risk, could be a reflection of adverse ionic
changes involving ICaL, IKs, and [Na]i dynamics that, upon
further deterioration, may facilitate arrhythmia initiation via an
increased likelihood of EAD generation.
Dynamics and Mechanisms of Ventricular HR Adaptation in
Humans
This study shows that simulated QTI and APD HR adapta-
tion dynamics in humans are in good qualitative and quantita-
tive agreement with the results reported in experimental and
clinical studies (3, 18, 22, 29, 35, 36). The simulation results
report two phases, fast and slow, in QTI and APD adaptation
dynamics, as previously reported in human experiments (18,
29, 35, 36) and also confirmed in experiments performed in this
study. The time constants for the two phases in human are fast 
30 s and slow  2 min, respectively, in both simulations and
experiments, in this study and in the literature (18, 36). Similar
adaptation dynamics are found in dogs, with a slightly longer
adaptation time compared with that in humans.
Our simulation results identify ICaL and IKs properties as the
main ionic determinants of the fast rate-dependent APD
changes in humans, with ICaL inactivation (Fig. 5A) playing a
major role, as reported in previous studies for humans (31), for
guinea pigs and rabbits (39), and for canine Purkinje fibers (6).
In addition, our results show that IKs activation kinetics also
contribute to the fast rate-dependent APD shortening (Fig. 5A),
as previously suggested (8, 13, 14).
Importantly, we also demonstrate that [Na]i dynamics play
a key role in the slow phase of APD adaptation (Fig. 5). INaK
inhibition, as it occurs in ischemia and heart failure patients,
results in slower [Na]i dynamics and delayed APD accom-
modation. The importance of INaK in the slow phase of APD
adaptation was previously suggested in animal species such as
dogs and guinea pigs (6, 10, 11, 14) but not in humans. Our
study quantifies it and confirms it for humans. In addition, we
show that it is primarily due to the role of INaK in regulating
[Na]i dynamics, and, indirectly, [Ca2]i dynamics through
the Na/Ca2 exchanger, rather than to alterations in the
electrogenic INaK current.
Ventricular rate adaptation as an indicator of arrhythmic
risk. Following a thorough validation of the simulated rate
adaptation dynamics described in Ventricular Rate Adaptation,
computer simulations were used to explore the link between
protracted HR adaptation and increased arrhythmic risk, as
previously suggested (22, 35). The main preclinical arrhythmic
risk biomarkers, namely, AP triangulation, probability of ICaL
reactivation, and APDR, were evaluated for conditions that
lead to delayed APD adaptation, to quantify risk of occurrence
of repolarization instabilities such as EADs and/or alternans
(5, 44).
As discussed in Ventricular Rate Adaption, delayed APD
adaptation could be caused by an increase in fast (via a
moderate reduction in f or xs or severe ICaL maximal con-
ductance block) or in slow (via INaK inhibition). Reduced f
values have been reported in dogs with chronic atrioventricular
block (1), which exhibit a high propensity for EADs and
Torsades de Pointes, whereas reduced xs is caused by a
mutation in the KCNQ1 gene that causes short QT syndrome
and is associated with high sudden cardiac death rate (4). Our
simulations also show that a less-pronounced initial APD rate
adaptation is associated with an increased AP triangulation
and, in the case of reduced xs, a higher probability of ICaL
reactivation, which facilitates EAD formation (25, 27, 30). Our
results are also consistent with experimental results showing
that the low incidence of EADs observed following the admin-
istration of amiodarone could be related to the ability of the
drug to slow ICaL (43) and decrease fast. Furthermore, in
patients who benefit from amiodarone therapy, the efficacy of
the drug has been explained by its ability to accelerate QTI rate
adaptation (37).
Reduced f or xs, and therefore increased fast, are also
associated with APDR slopes flattening, consistent with previ-
ous studies (23). The potential of APDR slopes as arrhythmic
risk predictors is somewhat controversial. Both experimental
and theoretical studies have shown that steep restitution slopes
facilitate a spiral wave breakup and a transition from ventric-
ular tachycardia to fibrillation (20, 32). However, conditions
associated with flat restitution slopes also allow wave break (9,
16) and could favor reentrant wave stability (17, 19). Thus
large fast values could also be associated with an increased
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arrhythmic risk due to the increased likelihood of the estab-
lishment of reentrant activity.
Both our simulation and experimental results show that INaK
plays a key role in determining slow. Large slow due to INaK
inhibition is associated with an increase in AP triangulation
and in the likelihood of ICaL reactivation (Fig. 6), indicating an
increased risk of EAD formation. Large slow values are also
associated with flat APDR slopes, which could favor the
stability of reentrant circuits and thus could increase arrhyth-
mic risk.
Our simulations show that, both in humans and dogs, EADs
develop for 60% INaK inhibition, a degree of inhibition ob-
served in ischemic disease and heart failure patients treated
with digitalis (7). In the experiments of INaK inhibition with 0.2
or 0.6 
M strophanthin G performed in the present study, no
EADs were observed; however, the degree of drug-induced
INaK inhibition is unknown and may be below 60%. Addition-
ally, the lack of EADs in the experiments might be explained
by the electrophysiological differences between the experimen-
tal (canine papillary muscle) and simulated preparations (ca-
nine Epi and human Endo/Mid/Epi tissue).
Limitations of the Study
In our study, a human ventricular model was used to explore
ventricular rate adaptation dynamics and simulation predic-
tions were validated using experimental and clinical data from
the literature and in a limited set of experiments in humans
performed in this study. Additional experiments and simula-
tions were performed in dogs because of its similarities with
humans in repolarization mechanisms. Our experimental and
theoretical results obtained in dogs and humans are qualita-
tively similar, although quantitative differences exist that could
be due to true animal species differences, differences in exper-
imental conditions, or model limitations. First, differences
exist in IK1 and IKs in canine versus human cardiac ventricular
tissue (28), which would lead to differences in ventricular rate
adaptation. Second, the human model (38) does not include a
description of the late sodium current and its IKs conductance
was defined based on APD measurements, which could explain
a larger contribution of IKs to APD adaptation in simulations
compared with experiments. Despite these limitations, the
present study provides new insights into the mechanisms of
ventricular rate adaptation and its link to proarrhythmic risk in
humans through a challenging combination of theoretical and
experimental work.
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